Enterprise Therapeutics: Vital service
Epidarex Capital-backed respiratory disease start-up Enterprise Therapeutics has named biotech entrepreneur John Ford as its new CEO. Ford previously co-founded Xention, Ario Pharma, and Metrion Biosciences.
Most recently, he was Chief Operating Officer at Dezima, which was acquired by Amgen in September 2015. He also led the team for Receptors and Channel Drug Discovery at BioFocus. Ford holds a BSc and a PhD in biochemistry and molecular biology from the University of Leeds.
pixabay.com - geralt
SK Bioscience
wikioedia.org - Von http://web2.airmail.net/uthman/specimens/index.html, Gemeinfrei, https://commons.wikimedia.org/w/index.php?curid=841015